The immune landscape and response to immune checkpoint blockade therapy in lymphoma
J Kline, J Godfrey, SM Ansell - Blood, The Journal of the …, 2020 - ashpublications.org
The clinical development of effective cancer immunotherapies, along with advances in
genomic analysis, has led to the identification of tumor environmental features that predict …
genomic analysis, has led to the identification of tumor environmental features that predict …
Targeting immune checkpoints in hematological malignancies
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …
T follicular helper cells in germinal center B cell selection and lymphomagenesis
MA Mintz, JG Cyster - Immunological reviews, 2020 - Wiley Online Library
Germinal centers (GCs) are confined anatomic regions where rapidly proliferating B cells
undergo somatic mutation and selection and eventual differentiation into memory B cells or …
undergo somatic mutation and selection and eventual differentiation into memory B cells or …
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
B Apollonio, F Spada, N Petrov… - The Journal of …, 2023 - Am Soc Clin Investig
Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has
highlighted the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) …
highlighted the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) …
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B‐cell lymphoma
R Shen, PP Xu, N Wang, HM Yi, L Dong… - Clinical and …, 2020 - Wiley Online Library
Background Diffuse large B‐cell lymphoma (DLBCL) is an aggressive subtype of lymphoma,
and multiple extranodal involvement (ENI) indicates adverse clinical outcomes. The aim of …
and multiple extranodal involvement (ENI) indicates adverse clinical outcomes. The aim of …
PD-1/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas
Abstract Purpose of Review Programmed cell death protein-1 (PD-1) is currently the most
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …
The immunology of DLBCL
T Takahara, S Nakamura, T Tsuzuki, A Satou - Cancers, 2023 - mdpi.com
Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common type of
malignant lymphoid neoplasm and includes morphologically and molecularly …
malignant lymphoid neoplasm and includes morphologically and molecularly …
Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
SD Smith, BG Till, MS Shadman… - British journal of …, 2020 - Wiley Online Library
Tumor programmed death‐ligand 1 (PD‐L1) expression in diffuse large B‐cell lymphoma
(DLBCL) is associated with inferior outcomes. The first‐line immunologically‐replete setting …
(DLBCL) is associated with inferior outcomes. The first‐line immunologically‐replete setting …
Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis
B Li, B Zhang, X Wang, Z Zeng, Z Huang… - …, 2020 - Taylor & Francis
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is considered a novel anti-
tumor target comparable to programmed cell death 1 ligand 1 (PD-L1). However, little is …
tumor target comparable to programmed cell death 1 ligand 1 (PD-L1). However, little is …